article thumbnail

WuXi Biologics, VISEN Partner to Make Lonapegsomatropin in Chengdu

The Pharma Data

Localized commercial production is anticipated to begin by 2028, following the completion of the technology transfer and necessary scale-up processes. VISEN Pharmaceuticals expects to obtain regulatory approval for lonapegsomatropin in China by 2025.

article thumbnail

Gilead Advances in HIV Market With Twice-Yearly Yeztugo, Leaving GSK Behind

The Pharma Data

GSK is also developing VH499, a capsid inhibitor, and is targeting the launch of its own twice-yearly HIV treatment and PrEP injectable between 2028 and 2030. The goal is clear: retain relevance in a market that Gilead continues to dominate. While Gilead currently holds a 51% share of the U.S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Incyte replaces CEO Hoppenot with dealmaker Meury

BioPharma Drive: Drug Pricing

But Jakafi’s main patents expire in 2028, a date that for years now has been on investors’ radar as they’ve pressed Incyte on what it expects will take the drug’s place. The company has had a good deal of success with Jakafi, a multipurpose drug approved to treat rare blood cancers and graft-versus-host disease. billion in sales.

article thumbnail

Price of World’s First Malaria Vaccine for Children in Endemic Countries Slashed by Over 50%, Now Under $5

The Pharma Data

In a landmark move, Bharat Biotech will progressively reduce the price of the RTS,S vaccine to below $5 per dose by 2028—a reduction of more than 50%. This announcement was made as part of their pledges to Gavi, the Vaccine Alliance, ahead of Gavi’s sixth replenishment cycle (Gavi 6.0) scheduled for 2026 to 2030.

article thumbnail

Keytruda fails lung and skin cancer trials, limiting further expansion

BioPharma Drive: Drug Pricing

The trial setbacks for Merck’s best-selling drug, which faces patent expiration in 2028, are a blow to the company’s plans for further indication expansion.

article thumbnail

Bristol Myers gets positive data in subcutaneous Opdivo trial

BioPharma Drive: Drug Pricing

An under-the-skin Opdivo shot produced similar results to an intravenous formulation in kidney cancer, giving Bristol Myers a chance at sustaining sales past a key patent expiration in 2028.

article thumbnail

How to Successfully Prepare for the HTAR Implementation in the EU

thought leadership

The HTAR will take effect in January 2025 for oncology and/or advanced therapy medicinal product (ATMP) therapies, with other therapies following a staggered implementation process, including orphan drugs in 2028 and all drugs in 2030.